Gregory L. Beatty, MD PhD

Dr. Beatty's clinical expertise is in the area of early clinical trials for the treatment of gastrointestinal malignancies including pancreas, esophageal and colon carcinomas. He has led the first clinical study of CD40 immunotherapy for pancreas cancer, the first in-human study of a novel inhibitor of indoleamine 2,3 deoxygenase, and is currently working to translate novel T cell adoptive therapies for pancreas cancer.

In addition to the translation of immunotherapeutic strategies for the treatment of gastrointestinal malignancies, Dr. Beatty's clinical research is focused on translating novel imaging strategies to the clinic to understand therapeutic responses to immunotherapy. His research also collaborates with radiation oncology to understand the role of radiation for activating immune responses against pancreatic carcinoma.

Based on early clinical findings supporting a role for immunotherapy in pancreatic carcinoma, Dr. Beatty's laboratory is using preclinical models of cancer to advance our understanding of the role of the immune system in regulating tumor biology with the primary goal to inform the development of novel immunotherapeutics for translation to the clinical setting.